Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...

Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate

Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate

The glomerular filtration rate (GFR) is a critical indicator of kidney health, reflecting how well the kidneys filter blood. Changes in GFR can signal potential kidney impairment, necessitating accurate measurement methods to monitor kidney function effectively.Various molecules can serve as markers for GFR measurement, with the ideal marker meeting several specific criteria. It must freely filter at the glomerulus, avoid reabsorption or secretion by the renal tubules, remain unmetabolized, not...

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area. This equation is...

Renal Failure: Dose Adjustments

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Systemic versus local regulation of vitamin D.

Current opinion in nephrology and hypertension·2026

Same author

Response to the "Letter to the Editor: Prebiotic Administration to Chronic Kidney Disease Patients Modifies Their Microbiome and Metabolism".

Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation·2026

Same author

Ferric carboxymaltose increases fracture risk in patients and reduces bone formation in mice with iron deficiency anemia.

Blood·2026

Same author

Cardiovascular Outcomes among New Users of GLP-1 Receptor Agonists Compared with DPP-4 Inhibitors and Sulfonylureas in Kidney Failure.

Journal of the American Society of Nephrology : JASN·2026

Same author

Effect of Clazakizumab on Neutrophil-Lymphocyte Ratio in Patients Receiving Hemodialysis: Secondary Analysis of the POSIBIL6ESKD Phase 2b Trial.

Clinical journal of the American Society of Nephrology : CJASN·2026

Same author

Fibroblast Growth Factor 23 Trajectories in Children and Association with CKD Progression: The CKD in Children Study.

Clinical journal of the American Society of Nephrology : CJASN·2026

Search research articles

Related Experiment Video

Updated: May 24, 2026

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

FGF23 in chronic kidney disease.

Patricia Wahl¹, Myles Wolf

¹Division of Nephrology and Hypertension, University of Miami Miller School of Medicine, Miami, FL, USA.

Advances in Experimental Medicine and Biology

|March 8, 2012

Summary

This summary is machine-generated.

Fibroblast growth factor 23 (FGF23) increases in chronic kidney disease (CKD) and may predict patient outcomes. Elevated FGF23 is linked to mortality and CKD progression, independent of phosphate levels.

More Related Videos

Assessment of Kidney Function in Mouse Models of Glomerular Disease

Assessment of Kidney Function in Mouse Models of Glomerular Disease

Published on: June 30, 2018

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

Related Experiment Videos

Last Updated: May 24, 2026

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

Assessment of Kidney Function in Mouse Models of Glomerular Disease

Assessment of Kidney Function in Mouse Models of Glomerular Disease

Published on: June 30, 2018

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

Area of Science:

Nephrology
Cardiology
Endocrinology

Background:

Chronic kidney disease (CKD) is a global health issue with high cardiovascular mortality.
Disordered phosphorus metabolism is implicated in CKD complications.
Fibroblast growth factor 23 (FGF23) plays a key role in mineral metabolism.

Purpose of the Study:

To investigate the role of FGF23 in CKD.
To explore FGF23 as a biomarker for CKD progression and mortality.

Main Methods:

Observational study analyzing FGF23 levels in CKD patients.
Correlation analysis between FGF23 levels and clinical outcomes (mortality, cardiovascular events, CKD progression).

Main Results:

FGF23 levels increase progressively in CKD patients.
Elevated FGF23 is associated with increased mortality, left ventricular hypertrophy, and CKD progression.
These associations remain significant even when serum phosphate levels are normal.

Conclusions:

FGF23 is a potential novel biomarker for identifying high-risk CKD patients.
Aggressive management of phosphorus metabolism may benefit CKD patients with elevated FGF23.
Further research is needed to explore FGF23's direct role in CKD-related tissue injury.